Zura Bio Ltd-A 2026年季度报告

FORM 10-Q_______________________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THETRANSITION PERIOD FROMTO Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May4, 2026, the registrant had 94,997,710 Class A Ordinary Shares outstanding. Table of Contents Cautionary Note Regarding Forward-Looking Statements3PART IFINANCIAL INFORMATION5Item 1.Financial Statements5Condensed Consolidated Balance Sheets5Condensed Consolidated Statements of Operations6Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Shareholders’Equity7Condensed Consolidated Statements of Cash Flows8Notes to Unaudited Condensed Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk30Item 4.Controls and Procedures30PART IIOTHER INFORMATION32 Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of thesafe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements include, but are notlimited to, statements regarding our and our management team’s expectations, hopes, beliefs, intentions or strategies regarding thefuture. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,including any underlying assumptions, are forward- looking statements. The words “anticipate,” “believe,” “continue,” “could,”“estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similarexpressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on the current expectations of Zura Bio Limited (the “Company” or “Zura”) and itsmanagement and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as ofthe date of such statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on ourforward-looking statements. These forward-looking statements involve a number of risks, uncertainties or other assumptions that maycause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, but are not limited to: •our expectations regarding our product candidates and their related benefits, and our beliefs regarding competing productcandidates or approved products, may not be achieved;•our vision and strategy may not be successful;•the timing of key events and initiation of our studies and release of clinical data may take longer than anticipated or may notbe achieved at all;•expectations regarding the potential general acceptability and maintenance of our product candidates by regulatoryauthorities, payors, physicia